Last reviewed · How we verify
NCT05110794
A Multiple-Dose Study of LY3502970 in Healthy Participants
Phase 1 trial testing LY3502970 in Healthy in 33 participants. Completed in 10 February 2022.
10 February 2022
Quick facts
| Lead sponsor | Eli Lilly and Company |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 33 |
| Start date | 5 November 2021 |
| Primary completion | 10 February 2022 |
| Estimated completion | 10 February 2022 |
| Sites | 1 location across Singapore |
Drugs / interventions tested
- LY3502970 — full drug profile →
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Eli Lilly and Company — full company profile →
Who can join
Adults 21 to 70, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main purpose of this study is to conduct blood tests to measure how much LY3502970 is in the bloodstream and how the body handles and eliminates LY3502970 in healthy participants in fed and fasted states. The study will also evaluate the safety and tolerability of LY3502970 in these participants. The study will last up to 49 days excluding the screening period.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist.
Ma X, Liu R, Pratt EJ, Benson CT, et al · · 2024 · cited 12× · PMID 38402332 · DOI 10.1007/s13300-024-01554-1
Verify or expand the search:
- PubMed search for NCT05110794
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of LY3502970
Trials testing the same drug.
- NCT06085482 — A Phase I Study of LY3502970 in Healthy Participants · Phase 1 · completed
- NCT06023095 — A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities · Phase 1 · completed
- NCT05936138 — A Study of LY3502970 in Participants With Normal and Impaired Renal Function · Phase 1 · completed
- NCT05882032 — A Study of LY3502970 in Participants With Impaired and Normal Liver Function · Phase 1 · completed
- NCT05841238 — A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants · Phase 1 · completed
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Eli Lilly and Company trials
Trials by the same sponsor.
- NCT07533006 — A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) · Phase 2 · not yet recruiting
- NCT07533019 — A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo · Phase 2 · not yet recruiting
- NCT07247357 — A Study of LY4064809 in Healthy Adult Chinese Participants · Phase 1 · completed
- NCT07124013 — A Study of Olomorasib (LY3537982) in Healthy Japanese Participants · Phase 1 · completed
- NCT07030127 — A Study of LY3985863 in Healthy Participants · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05110794 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eli Lilly and Company
- Last refreshed: 23 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05110794.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing